US EditionAI Firm Graph Raises $3 Million in Seed Funding From Bessemer Venture Partners to Disrupt $8 Billion Pharmacovigilance Market
Graph AI's AI-driven platform improves drug safety monitoring with up to 70% efficiency gains and 90% faster regulatory reporting, disrupting the $8 billion pharmacovigilance market.
- On Oct. 15, 2025, San Francisco-based Graph AI said it closed a $3 million seed round led by Bessemer Venture Partners.
- Targeting the $8 billion pharmacovigilance market, Graph AI said the funding will accelerate product innovation and engineering team expansion.
- Early commercial results demonstrate customers reported up to 70% efficiency gains and 90% faster regulatory reporting, with enterprise traction spanning over 7,000 drugs.
- Nithin Kaimal of Bessemer Venture Partners said they are excited to partner with Graph AI, which is led by Raghav Parvataraju, as it redefines labour‑intensive pharmacovigilance through AI.
- Automating pharmacovigilance workflows, Graph's human-in-the-loop approach replaces pharma services firms that outsource manual ADE reporting, positioning Graph as an AI-native challenger in pharma and life sciences.
30 Articles
30 Articles
Graph AI raises $3 million seed funding for drug safety platform
AI life sciences startup Graph AI has secured $3 million in seed funding to revolutionise pharmacovigilance. The California-based startup leverages AI-driven automation to address the inefficiencies and errors in traditional drug safety monitoring. This funding will accelerate product innovation and global market expansion for their SaaS platform.
AI firm Graph Raises $3 million in Seed Funding from Bessemer Venture Partners
According to the company, the pharmacovigilance market is valued at USD 8 billion, and Graph AI, with the funding, will be able to enter the new wave of AI-native challengers reshaping the pharma and life sciences landscape, with a sharp focus.
Hanford Sentinel
AI firm Graph raises $3 million in Seed Funding from Bessemer Venture Partners to disrupt $8 billion pharmacovigilance market
SAN FRANCISCO, Oct. 15, 2025 /PRNewswire/ -- California based Graph AI, focused on patient safety and pharmacovigilance, announced its $3 million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering…
Graph AI raises $3 million seed funding to advance AI-based pharmacovigilance platform - Express Pharma
Graph AI, a California-based AI life sciences company focused on patient safety and pharmacovigilance, announced the close of its $3 million Seed round led by Bessemer Venture Partners. The investment will enable Graph AI to accelerate product innovation, expand its engineering team, and drive global market adoption. Graph AI operates within the $8 billion pharmacovigilance market, which is mandated by global drug regulatory authorities. Pharmac…
Graph AI Raises $3 Mn To Automate Drug Safety Monitoring for Pharma Firms Graph AI Raises $3 Mn To Automate Drug Safety Monitoring for Pharma Firms
Pharmaceutical-sector focussed AI startup Graph AI has secured $3 Mn (around INR 26.37 Cr) in its seed funding round led by Bessemer Venture Partners. In a statement, the startup said it will use the funds for product innovation, team expansion, and fast-tracking market adoption for its proprietary pharmacovigilance automation platform. Founded last year by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bord…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
